Automated Platform Microfluidic-based Clinical Immunoanalyzer
The μTASWako i30 is a commercially available microfluidic-based clinical immunoanalyzer for in vitro diagnostic use in the United States and Canada. The microfluidic technology minimizes instrument hands-on time while maximizing efficiency through integration and automation of clinical laboratory processes. Currently FUJIFILM Wako is offering AFP-L3 and DCP tests on the μTASWako i30.
-Nine minutes to first result, two minutes per subsequent result
-Throughput: 25 results per hour
-Superb analytical sensitivity
-Accurate and precise performance
-Up to six analyte measurements per sample
-Random assay selection per sample
-Short setup time – 10 minutesTwo-hour walk away time
-Automated calibration and quality control
-STAT capability
-LIS integration capability
-RFID tag enabled reagent tracking
-Ready to use reagents
-Intuitive touch panel operation
-On-board refrigerated reagents
-Easy access to consumables and waste
-Minimal routine maintenance
μTASWako® AFP-L3:
The μTASWako AFP-L3 Immunological Test System is an in vitro device that consists of reagents used with the μTASWako i30 Immunoanalyzer to quantitatively measure, by immunochemical techniques, AFP-L3% in human serum. The device is intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma (HCC) in conjunction with other laboratory findings, imaging studies and clinical assessment. Patients with elevated AFP-L3% values (>= 10%) have been shown to be associated with an increase in the risk of developing HCC within the next 21 months and should be more intensely evaluated for evidence of HCC according to the existing HCC practice guidelines in oncology.
μTASWako® DCP:
The μTASWako DCP Immunological Test System is an in vitro device that consists of reagents used with the μTASWako i30 Immunoanalyzer to quantitatively measure, by immunochemical techniques, des-gamma-carboxyprothrombin (DCP) in human serum. The device is intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma (HCC) in conjunction with other laboratory findings, imaging studies, and clinical assessment.
Basic Procedure
Operation on μTASWako® i30 Immunoanalyzer
